Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Project: Research project

Project Details

StatusFinished
Effective start/end date7/27/17 → 7/27/20

Funding

  • ICON Clinical Research, L.P. (Prot #GS-US-436-4092)
  • Gilead Sciences, Inc. (Prot #GS-US-436-4092)